Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 24: 1751-1754, 1978;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Piepkorn, M. W.
Right arrow Articles by Labbe, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piepkorn, M. W.
Right arrow Articles by Labbe, R. F.

Clinical Chemistry, Vol 24, 1751-1754, Copyright © 1978 by American Association for Clinical Chemistry

Modified erythrocyte uroporphyrinogen I synthase assay, and its clinical interpretation

MW Piepkorn, P Hamernyik and RF Labbe

Assay of erythrocyte uroporphyrinogen I synthase is an accepted diagnostic test for acute intermittent porphyria, particularly in those individuals who are asymptomatic or in whom the disease is not biochemically manifested by excretion of excess porphyrin precursor. The assay described is based upon a coupled-enzyme procedure in which added delta-aminolevulinic acid and its dehydratase present in erythrocytes are used to generate porphobilinogen as substrate for uroporphyrinogen synthase. Zinc and dithiothreitol are added with preincubation to give maximum activity and reproducibility. These agents also prevent inhibition by lead. Healthy young women had a mean activity of 40 nmol of porphyrin formed per milliliter of erythrocytes per hour, men and activity of 38 nmol/ml/h. Preparation of control specimens is described. This assay gave within-day CVs ranging from 1.9 to 2.8%. Precautions in interpretation of results are discussed.


The following articles in journals at HighWire Press have cited this article:


Home page
 Annals of Clinical & Laboratory ScienceHome page
J. G. Donnelly, S. Detombe, and J. T. Hindmarsh
Single-Strand Conformational Polymorphism and Denaturing Gradient Gel Electrophoresis in Screening for Variegate Porphyria: Identification of Two New Mutations
Ann. Clin. Lab. Sci., April 1, 2002; 32(2): 107 - 113.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. T. Hindmarsh, L. Oliveras, and D. C. Greenway
Plasma Porphyrins in the Porphyrias
Clin. Chem., July 1, 1999; 45(7): 1070 - 1076.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
S. B. Dover, A. Graham, M. R. Moore, and K. E. L. McColl
Lofepramine--a safe anti-depressant in acute hepatic porphyria?
J Psychopharmacol, January 1, 1994; 8(2): 104 - 108.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
H. A. Peters, A. Gocmen, D. J. Cripps, G. T. Bryan, and I. Dogramaci
Epidemiology of Hexachlorobenzene-Induced Porphyria in Turkey: Clinical and Laboratory Follow-up After 25 Years
Arch Neurol, December 1, 1982; 39(12): 744 - 749.
[Abstract] [PDF]

Home page
 JAMAHome page
T. D. Bird, D. M. Wallace, and R. F. Labbe
The Porphyria, Plumbism, Pottery Puzzle
JAMA, February 12, 1982; 247(6): 813 - 814.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1978 by the American Association for Clinical Chemistry.